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Abstract
Background and Aims: The expression of the jumping translocation breakpoint (JTB) gene is upregulated in malignant liver
tissues; however, JTB is associated with unbalanced translocations in many other types of cancer that suppress JTB
expression. No comprehensive analysis on its function in human hepatocellular carcinoma (HCC) has been performed to
date. We aimed to define the biological consequences for interaction between JTB and HBsAg in HCC cell lines.
Methods: We employed the stable transfection to establish small HBsAg expressing HepG2 cell line, and stably silenced the
JTB expression using short hairpin RNA in HepG2 cell line. The effects of JTB and small HBsAg in vitro were determined by
assessing cell apoptosis and motility.
Results: Silencing of JTB expression promoted cancer cell motility and reduced cell apoptosis, which was significantly
enhanced by HBs expression. Expression of HBsAg inhibited the translocation of JTB to the mitochondria. Furthermore,
silencing of the JTB resulted in an increase in the phosphorylation of p65 in HepG2 cells and HepG2-HBs cells, whereas
HBsAg expression decreased the phosphorylation of p65. The silencing of JTB in HepG2-HBs cells conferred increased
advantages in cell motility and anti-apoptosis.
Conclusion: HBsAg inhibited the translocation of JTB to the mitochondria and decreased the phosphorylation of p65
through the interaction with JTB, After JTB knockdown, HBsAg exhibited a stronger potential to promote tumor
progression. Our data suggested that JTB act as a tumor suppressor gene in regards to HBV infection and its activation
might be applied as a therapeutic strategy for in control of HBV related HCC development.
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Introduction
Complications of chronic HBV (CHB), including liver failure
and hepatocellular carcinoma (HCC), which is one of the greatest
risk factors for the development of HCC and the 10th leading
cause of mortality worldwide [1,2,3]. In the past two decades,
a number of strong findings have shown that the X protein (HBX)
acts as a transactivation factor and is clearly associated with
tumorigenesis [4,5,6]. Functions in the carcinogenesis of other
proteins, such as HBs, that are encoded by HBV are also related to
liver tumor development [7,8,9,10,11]. HBV encodes three
envelope proteins in the pre-S/S open reading frame, which are
named the large, middle, and small surface proteins [7]. A number
of truncated surface gene mutants with a partially deleted pre-S
region have been identified; one of the major mutant types is the
deletion of the pre-S2 region (pre-S2D). These pre-S2D mutants
have become increasingly prevalent in the serum and liver tissues
of patients with chronic HBV infection and HCC [12,13]. The
overexpression of pre-S2D (S2 characterized by the deletion of the
pre-S2 region) large surface proteins has been demonstrated in the
induction of endoplasmic reticulum (ER) stress [14], oxidative
stress, DNA damage [15], COX-2 expression [16], cyclin A
expression [17] and the degradation of p27Kip1 [18]. These
results suggest that the expression of the HBV large surface
protein, especially the pre-S2D mutant, might be important for
hepatocarcinogenesis. However, determining putative additional
roles for the S protein require further investigation.
Current cytogenetic evidence indicates the important role of the
1q21-q22 region in drug resistance [19], tumor metastasis [20]
and a shorter duration of patient survival. Therefore, the function
of the genes that are located proximal to this region may be
associated with the process that accounts for the frequent
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translocation of the region in many types of tumors. A
comparative genomic hybridization analysis of HCC indicates
frequent gains of 1 q and an amplicon at 1q21-q22 [20]. Jumping
translocation breakpoint (JTB) is a gene that is located on human
chromosome 1 at q21 and undergoes an unbalanced translocation.
Although JTB expression is suppressed in many cancers of
different organs [21,22], some studies have reported the over-
expression of JTB in cases of hepatocellular carcinoma [20].
Therefore, the biological function of JTB remains unclear.
Previous studies have raised the possibility that aberrations in
the structure or expression of JTB induce neoplastic changes in
cells, such as deregulated cell growth and/or death through
mitochondrial dysfunction [22].
Our previous studies have suggested that there is an interaction
between HBsAg and JTB, such as a recombination event [23], and
that JTB may play a critical role in oncogenesis in the liver.
However, the role of the interaction between HBs and JTB in liver
tumorigenesis remains unknown. In this study, we aimed to
investigate the functional changes in HepG2 cells by evaluating
the interaction between JTB and HBs.
Materials and Methods
Cell culture, treatment and transfection
HepG2, L-02, HuH-7 and GES cells were grown in DMEM
medium, SGC7901 cell was in RPMI1640, and AGS cell was in
F12K medium, respectively. All cells were cultured in mediums
with 10% fetal calf serum at 37uC in a 5% CO2 humidified
atmosphere. The HCC cell lines HepG2, L-02 and HuH-7 were
provided by the Cell Bank of Shanghai Institute of Cell Biology,
Chinese Academy of Sciences, Shanghai, China. The HCC cells
were treated with 0.6 mM H2O2 for 8 h. The HepG2 cells were
transfected with 2 mg of the pCMV-HBsAg vector using FuGENE
HD (Roche, Indianapolis, IN) in six-well plates. After 48 hours of
transfection, the cells were split 1:10 and selected with 600 mg/mL
G418 (Sigma, St Louis, MO) for 2 weeks. The G418-resistant
colonies were pooled together, and the HBs-expressing clones
were identified by immunoblotting and maintained with 600 mg/
mL G418. HepG2 cells were transfected with siJTB (pcPUR+U6-
siJTB) or a PU6 (pcPUR+U6-siRenilla) plasmid using the
FuGENE HD (Roche, Indianapolis, IN). Puromycin (2.0 mg/ml)
was used to screen stably transfected clones. The expression of the
JTB protein was examined by Western blotting analysis using an
antibody against JTB (these experiments were repeated three
times) to validate the efficiency of the constructs to inhibit target
gene expression.
Stable knockdown of JTB
A plasmid containing an RNA interference sequence that
targeted HepG2 was constructed as previously described [24,25],
and a line of stable HepG2 knockdown cells were also established
as previously described [26,27]. One pair of the siJTB sequence
was Forward primer, 59- CACCGCGGAAGAGTGTTCTT-
CATA CGTGTGCTGTCCGTATGGAGAG-
CACTCTTCTGCTTTTT -39, and Reverse primer, 59- GCA-
TAAAAAGCAGAAGAGTGC TCTCCATACGGACAGC
ACACGTATGAAGAACACTCTTCCGC -39. HepG2 cells
were transfected with pcPUR+U6-siJTB or pcPUR+U6-siRenilla
(control) and selected as puromycin-resistant pools. Quantitative
reverse transcription-PCR (qRT-PCR) was performed to confirm
the JTB mRNA suppression using the primers 59-
CGGGCTAAAACTACCCCTGAG -39 and 59-TGAGCGG-
CAGCTTTTGAACT-39.
Western blot analysis and co-immunoprecipitation
Cells were re-suspended in lysis buffer containing a protease
inhibitor cocktail, and the extracted proteins were separated using
10–15% SDS–PAGE gels. b-actin was used as a loading control.
Antibodies against b-actin, tubulin, coxIV, bcl-XL, caspase-9,
cytoC, MMP-2, PARP, p-p65 (ser536) and p65 were obtained
from Cell Signaling Technology; JTB antibody was obtained from
Sigma Aldrich. Co-immunoprecipitation was performed using
whole-cell lysates and antibodies against JTB and HBsAg. The
immunoprecipitation was performed with A/G agarose beads that
were coated with anti-JTB or anti-HBs, and the proteins were
detected using anti-JTB and anti-HBs antibodies via western blot
analysis. Mouse or rabbit immunoglobulin IgGs were used as
negative controls.
Flow cytometric and apoptosis assays
HCC cells were used for the apoptosis assays. The HCC cells
were seeded into a 24-well culture dish and treated with 0.6 mM
H2O2 for 8 h. The treated cells were washed with PBS three times
followed by trypsinization. The harvested cells were stained with
the Annexin V-FITC apoptosis assay kit (Kaiji Corp., Nanjing,
China) according to the manufacturers’ manual. Finally, the cells
were assessed for apoptosis ratios using flow cytometry. The
experiments were performed in triplicate.
RNA extraction, reverse transcription and real-time PCR
Briefly, first-strand cDNA was synthesized using the ImProm-II
reverse transcription system (Promega, Madison, WI) and was
subjected to quantitative PCR using a Light Cycler 480 system
(Roche, Indianapolis, IN). The primer sequences were as follows:
MMP-2, forward 59-TGATCTTGACCAGAATACCATCGA- 39
and reverse 59-GGCTTGCGAGG GAA G AAGTT- 39;
GAPDH: forward 59-CAAGGTCATCCATG ACAACTTTG-
39 and reverse 59-GTC CACCACCCTGTTGCTGTAG-39. Bcl-
XL: forward 59- GTGAATGGAGCCACTGCGC A- 39 and
reverse 59-CCCCATCCCGGAAGAGTTCA- 39.
Transwell invasion and wound healing
Transwell invasion assays were performed with 8.0-mm pore
inserts in a 24-well transwell plate. For this assay, the HCC cell
lines were added to the upper chamber of a Transwell with
0.5 mg/mL collagen type l (BD Bioscience, San Jose, CA)-coated
filters for the invasion assay. DMEM with 10% fetal bovine serum
and 1% of each antibiotic was added to the lower chamber, and
the cells were allowed to incubate for 16 hours. Invading cells were
quantified after Gentian violet staining. Each experiment was
performed in triplicate, and the data were expressed as mean
values. A wound-healing assay was performed in 24-well plates.
Tumor cells in medium containing 10% FBS were seeded into 24-
well plates (Corning, CA). After the cells grew to confluence, made
the wounds using sterile pipette tips, then, cells were washed with
PBS and refreshed with medium with 10% FBS. The photographs
were token at 0 and 24 h.
Isolation of cytosolic and mitochondrial fractions
The isolation of cytosolic and mitochondrial fractions was
performed using the ApoAlert kit. After H2O2 treatment, the cells
were plated in 75-cm2 flasks and harvested by trypsinization. A
total of 56107 cells were centrifuged at 6006 g for 5 min at 4uC.
The pellet was resuspended in 0.8 ml of ice-cold fractionation
BufferMix, incubated on ice for 15 min, and homogenized with
a Dounce tissue grinder on ice. The homogenate was subsequently
transferred to a microcentrifuge tube and centrifuged at 7006 g
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for 10 min at 4uC. The supernatant was collected and transferred
to a fresh microcentrifuge tube and centrifuged at 10,0006 g for
25 min at 4uC. The cytosolic fraction was collected, and the pellet,
representing the mitochondria-containing fraction, was resus-
pended in 100 mL of fractionation BufferMix. The protein
concentration was determined using the BCA method with bovine
serum albumin as standard. The cytochrome c in the cytosolic and
mitochondrial fractions was analyzed using western blot analysis.
Cell immunofluorescence analysis
For cell immunofluorescence, 56104 HepG2 and HepG2-HBs
cells were plated onto coverslips in 24-well plates for 24 hours.
The cells were fixed in 4% paraformaldehyde for 10 minutes,
permeabilized with 0.1% Triton X-100 for 10 minutes, and
blocked with 10% BSA for 30 minutes. Next, the cells were
incubated at room temperature with or without primary anti-JTB,
anti-HBs or anti-coxIV antibodies for 1 hour followed by the
respective secondary antibodies Texas Red goat anti-mouse
antibodies and fluorescein isothiocyanate (FITC). The nuclei were
counterstained with DAPI dye before the slides were mounted
with the FluorSave reagent. The slides were observed under an
Olympus FV-500 fluorescent microscope.
Luciferase reporter gene assays
The transcriptional activity of the p65-responsive element was
assessed using the p65 reporter assay. Briefly, the p65 and negative
control reporter plasmids were separately transfected into HCC
cells in replicate wells using Lipofectamine 2000 reagent (Invitro-
gen). Two days after transfection, the luciferase activity was
determined using the dual-luciferase reporter assay system
(Promega).
Figure 1. JTB interaction with HBs in HepG2 cells. (A) The expression levels of JTB in HCC cell lines and normal liver cell, JTB in gastric cancer
cells and normal gastric cell were determined using western blot analysis. HBs was detected for stable transfected cells. b-actin was used as a loading
control. (B) Immunoprecipitation was performed as described in the Materials and Methods section. JTB and HBs were detected by western blot
analysis. The whole-cell lysate was used as a positive control. (C) A western blot showing the distribution of JTB in the cytosolic and mitochondrial
subfractions. Tubulin and coxIV were used as cytosolic and mitochondrial markers, respectively. (D) The effects of JTB on the mitochondrial
localization and co-localization of JTB and HBs. Cellular localization by the immunocytochemical analysis of JTB and HBs in HepG2 cells using (a, b)
FITC-labeled anti-JTB (green) and Texas red-labeled anti-coxIV (red) antibodies, (d, e) FITC-labeled anti-JTB (green) and Texas red-labeled anti-HBs
(red) antibodies, (g, h) and FITC-labeled anti-JTB FITC (green) and Texas red-labeled anti-coxIV (red) antibodies under confocal microscopy. To label
the nuclei, 49,6-diamidino-2-phenylindole (DAPI) was used (blue). Bars, 10 mm.
doi:10.1371/journal.pone.0036914.g001
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Statistical analysis
The data were expressed as the mean 6 standard error of the
mean (SEM). Experimental differences were analyzed using SPSS
v11 with the 2-tailed t-test and with P,0.05 defined as the selected
level of significance.
Results
JTB binds HBs, and HBs expression reduces the
mitochondrial localization of JTB
To explore the expression of JTB in different liver cancer cell
lines, we examined the nomal liver cells and several liver cancer
cell lines on JTB expression by western blotting. Meanwhile we
established HepG2 stable cell line expressing HBsAg and silenced
JTB expression using short hairpin RNA stable produced in
HepG2 cell line. The JTB expression in the HCC cell lines
recapitulated the pattern of expression in the human HCCs. The
cell lines expressed high (HepG2 and Huh7 cells), intermediate (L-
02 cells), or low-to-undetectable (HepG2-JTBi and HepG2-HBs-
JTBi cells) levels of JTB. In addition, gastric cancer SGC7901 and
AGS cell lines showed the lower expression level of JTB compared
with normal gastric GES cell (Figure 1 A).
We have previously shown that the JTB protein binds to the
HBV surface antigen (HBsAg). However, we used JTB delivered
exogenously by transfection. To further illustrate the relationship
between the combination of JTB and HBsAg. Recently, we used
the endogenous JTB in HepG2 cells to detect whether a combined
effect of the endogenous JTB protein and HBs existed. The cell
lysates were subjected to immunoprecipitation with the anti-JTB
antibody followed by western blot analysis with anti-JTB and anti-
HBs antibodies; another set of cell lysates were also subjected to
immunoprecipitation with the anti-HBs antibody followed by
western blot analysis with anti-JTB and anti-HBs antibodies. The
whole-cell lysate was used as a positive control, and immunoglob-
ulin IgG was used as a negative control. The results showed that
the anti-JTB antibody precipitated HBs and that the anti-HBs
antibody precipitated JTB (Figure 1B).
Furthermore, we applied immunofluorescence confocal tech-
nology to prove the combination of HBsAg and JTB. We
determined the localization of JTB in HBs-transfected HepG2
cells using western blot analysis (Figure 1C) and immunocyto-
chemistry (Figure 1D). JTB was localized to the mitochondria
(Figure 1D a, b and c), and HBs co-localized with JTB (Figure 1D
d, e and f). The expression of HBs decreased the translocation of
JTB to the mitochondria and caused the cytoplasmic accumula-
tion of JTB, which inhibited the co-localization of JTB with the
mitochondria marker cox IV (Figure 1D g, h and i). The change of
JTB cellular localization could make effect on cell function. In the
next experiments, we will explore the cell function involved
apoptosis and motility after the change of cellular localization.
JTB knockdown suppresses H2O2-induced apoptosis by
increasing Bcl-XL
The exposure of cells to H2O2 induces apoptosis through
pathways that involve the disruption of normal mitochondrial
function. One key mechanism involves the opening of the
mitochondrial permeability transition pores (PTPs) that allow the
passage of some small pro-apoptotic molecules, such as cyto-
chrome c into the cytoplasm [28,29]. Previous studies have
reported that the opening of PTPs increases when the mitochon-
drial membrane potential decreases [30].
To explore the role of JTB and interaction with HBsAg on cell
apoptosis, we used H2O2 to induce oxidative stress which cause
the cell apoptosis. The response to H2O2 -induced apoptosis in
different liver cancer cell lines was examined by Flow cytometric
and apoptosis assays. As shown in Figure 2A and B, the Annexin V
signal significantly decreased in cells knocked down for JTB
compared to cells transfected with the control pU6-sh plasmid.
HBs expression enhanced the effect of decreasing the number of
Annexin V-positive cells in the population of HepG2 cells. Our
results show that JTB and HBs act cooperatively to reduce
apoptosis. HBs expression was expected to reduce the sensitivity of
a cell to H2O2-induced apoptosis after JTB knockdown, and HBs
did not exhibit anti-apoptotic effects in the presence of JTB.
Knockdown of JTB induced Bcl-XL upregulation(Figure 2C and
D). Cytochrome c accumulated in the cytosol of vector-transfected
cells and was markedly abundant compared to that found in the
cytosol of cells knocked down for JTB (Figure 2E). In the
cytoplasm, cytochrome c binds to APAF-1 to form an apoptosome,
which activates caspase 9 (Figure 2F). H2O2-induced cell apoptosis
was reduced in the cells with JTB knockdown, and the disruption
of the mitochondrial transmembrane potential (MTP) and
cytochrome c leakage were reduced. The anti-apoptotic gene
Bcl-XL was also highly expressed. In the hepatoma cells, JTB
expression protected the cells against H2O2 injury. This effect may
be associated with the preservation of mitochondria. Upregulation
of Bcl-XL plays a crucial confrontation to apoptosis. JTB regulate
the Bcl-XL expression through some unknown pathway.
Silencing of JTB increases cell motility, which is enhanced
by HBs
To further explore the biological function of JTB, We
determined the effects of HBs and JTB silencing on cell invasion
and wound healing (Figure 3A–D). As expected, JTB silencing
significantly promoted both of these processes, whereas HBs did
not induce migration or invasion in HepG2 cells. To show the
effect of JTB on HBs, we stably silenced JTB using its shRNA in
the HepG2-HBs cells, which strongly express JTB. Invasion assays
were performed to determine the effect of JTB silencing on cancer
cell motility, and the cell numbers were counted (Figure 3C) and
recorded (Figure 3A) using a microscope. As shown in Figure 3A
and B, JTB knockdown increased cell migration and invasion,
which was significantly enhanced by HBs expression. Further-
more, to explore the molecular mechanisms in cell migration and
invasion, we examined whether JTB regulates cell motility through
the MMP-2 protein and mRNA expression. We found that the
level of MMP-2 expression was significantly enhanced in
HBs+JTBi cells in comparison to pU6-JTBi cells (Figure 3E–F).
These results suggest that JTB could regulate the expression of
MMP2 and affect the cell motility, while the presence of HBsAg
play has an important biological synergy function with JTB.
Silencing of JTB increases p65 activity, and HBs enhances
this effection
Summarize the previous results, JTB and HBsAg have new
biological functions on cell apoptosis and motility. We initially
explore the possible associated signal transduction pathway. We
examined the effect of JTB and HBs on NF-kB activation.
Canonical NF-kB activation was assessed using phospho-immu-
noblot analysis (Figure 4A) and luciferase activity assay (Figure 4B).
Immunoblot analysis for phospho-p65 revealed an increased
phosphorylation of p65 in pU6-JTBi and HBs+JTBi cells,
although the level of phospho-p65 was significantly increased in
HBs+JTBi cells compared to that in pU6-JTBi cells. The same
trends were demonstrated in luciferase activity assay. These results
show the biological activity of HBs in HCC progression. The
presence of JTB masked the function of HBs. In addition, we are
HBsAg Inhibits the JTB in HepG2 Cells
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36914
Figure 2. Stable knockdown of JTB in HCC cells decreases cell apoptosis. HepG2 cells were treated with 0.6 mM H2O2 for 8 h. (A) The
percentage of apoptotic cells in HepG2 cells. (B) Quantification of apoptosis cells in different HepG2 cells. The percentage of apoptotic cells was
determined using cyto-fluorimetric analysis with Annexin-V and PI labeling. The data were obtained from three analyses (*P,0.05). (C and D) The
level of the Bcl-XL mRNA in HepG2 cells as measured using qRT-PCR. The results represent the mean of three amplifications and were calculated
using the 2 exp(2ggCt) formula. b-actin mRNA in HepG2 cells was used as a control (*P,0.05). (E) Western blot analysis of the cytosolic and
HBsAg Inhibits the JTB in HepG2 Cells
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trying to find more upstream signaling molecules. We used the
protein chip technique to detect changes in the major protein
kinase activities in different HCC cell lines, and the results of this
experiment revealed that several protein kinases, such as AKT,
ERK, RSK1, GSK-3b, showed dramatic changes in their level of
phosphorylation (Figure 4C). Thus, we detected the phosphory-
lation level of three protein kinases using western blot analysis
(Figure 4D), and the results were consistent with those obtained
with the protein chip technique.
Discussion
The hepatitis B surface antigen (HBsAg) was the Nobel Prize
discovery that identified the hepatitis B virus (HBV) approximately
40 years ago. Currently, HBsAg remains the hallmark of overt
mitochondrial cytochrome c levels in HepG2 cells induced by H2O2 after 8h. (F) Uncleaved (p47) and activated caspase-9 (p37) were detected by
western blot analysis in HepG2 cells induced by H2O2 after 8 h.
doi:10.1371/journal.pone.0036914.g002
Figure 3. Transient knock-down of JTB promotes migration and invasion in the HCC cells expressing high levels of JTB. (A) Images
and graphs (C, *P,0.05) from invasion assay at 16 h; (B) Images and graphs (D, *P,0.05) from migration assay the migrating ability of control cells at
24 h was considered as 1 in (D); The MMP-2 protein expression was detected using western blot analysis (E), and the mRNA expression was quantified
using qRT-PCR (F).
doi:10.1371/journal.pone.0036914.g003
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HBV infection [3]. Hildt et al. found that the Pre-S2 members of
the regulatory protein family, including L-HBs and truncated M-
HBs, are transcriptional activators that trigger the activation of
tumor promoters [31]. The small (S) protein is expressed at the
highest levels and is predominant in virions and subviral particles.
However, the role of S-HBs in HBV-induced oncogenesis is not
well understood. Therefore, the present study was designed to
verify the function of HBs via the interaction of HBs with JTB.
Our previous study had shown that the viral envelope protein
HBs interacts with JTB. In addition, S-HBs and L-HBs
functionally bind JTB, which presumably indicates that the
binding site may be located in the S region of viral HBs [23].
JTB is upregulated in liver cancer cells [20], and previous research
has demonstrated that JTB is downregulated in other cancer
tissues [22]. It has been shown that the elevation of Sp1 protein
expression is a critical factor in tumor development and growth
and metastasis, and it is the promoter of JTB contains a sp1-
binding site [21]. Therefore, JTB expression may be elevated in
human tumors. In the current study, the overexpression of JTB
reduced neoplastic changes in cells, such as regulated cell death via
mitochondrial dysfunction. We also found that overexpression of
JTB lead to apoptosis in normal liver L-02 cell line induced by
H2O2, JTB can increase the activity of caspase9 and promote the
cleavage of PARP (Figure S1 and data S1). When the JTB gene
Figure 4. Activity of p65 and other protein kinases in HCC cell lines. The transcriptional activity of p65 was measured indirectly using
luciferase reporter assays and normalized against TK-renilla. (A) Immunoblot analysis for phospho-p65 and total p65 protein expression. Increased
phosphorylation of p65 was detected in both pU6-JTBi and HBs+JTBi cells, whereas HBs inhibited p65 phosphorylation. (B) Transcriptional activity of
the p65 promoter in HepG2 cells using the luciferase activity assay was consistent with the level of p65 phosphorylation. The data were expressed as
the mean of three experiments and as a percentage of the p65 promoter activity compared to that in the HepG2-vector cells (100%). (C) The results of
the Human Phospho-MAPK Array Kit (R&D Systems, Inc.) In addition, we determined the relative levels of phosphorylated mitogen-activated protein
kinases (MAPKs) and other serine/threonine kinases. (D) The phosphorylation levels of AKT, ERK and GSK-3b were detected by western blot analysis.
doi:10.1371/journal.pone.0036914.g004
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undergoes an unbalanced translocation, its expression is sup-
pressed; therefore, we concluded that JTB is a tumor suppressor
gene. The jumping translocation of the JTB gene eventually leads
to the development of tumors to promote tumor differentiation
and staging.
When we stably transfected the HepG2 cells with HBs, the JTB
protein interacted with HBs and inhibited the translocation of JTB
to the mitochondria. The interaction between JTB and its specific
binding protein, HBs, mediates several cellular functions. Our data
indicate the possibility that blocking JTB may increase the
metastatic potential and reduce the apoptotic potential of cancer
cells. However, transfection of HBs alone into HepG2 cells did not
perturb apoptosis or metastasis. Surprisingly, blocking JTB in
pCMV-HBs cells seems to enhance anti-apoptotic and metastastic
activities compared to that in HepG2 cells. These results suggest
that HBs has a biological activity that is JTB-independent. We
showed that JTB inhibited the phosphorylation and reduced the
biological activity of p65; thus, we speculate that the presence of
HBs may sequester JTB in the cytoplasm and decrease the
phosphorylation of p65. Blocking or knockdown of JTB may
promote the HBs-mediated phosphorylation of p65.
NF-kB plays a well-known function in the regulation of immune
responses and inflammation, but growing evidences support
a major role in oncogenesis. In vitro, neutralizing the interaction
of JTB and HBs significantly impaired the metastasis of liver
cancer cells and cell apoptosis. This result suggests that JTB is
important for the function of HBs in HCC cells and indicates the
possibility that the strengthening of JTB/HBs interactions may be
a strategy to prevent cancer cell metastasis and antiapoptosis. JTB
expression reduces tumor metastasis and antiapoptosis by de-
creasing p65 activity. p65 regulates the expression of genes
involved in many processes that play a key role in the development
and progression of cancer such as proliferation, migration and
apoptosis. The Bcl-XL protein plays an important role in
maintaining the intergrity of mitochondrial thereby inhibiting
the release of factors which activate the pro-apoptotic caspase
cascade [32]. MMP-2 is known to play a crucial role in tumor
invasion via its ability to degrade basement membrane collagens.
It plays important roles in cancer development and aggression.
p65 directly activates expression of the apoptosis inhibitor Bcl-XL
[33] and matrix-modifying enzyme MMP-2 [34]. The activation
of HBs following JTB knockdown may protect cell from apoptosis
and trigger the degradation of extracellular matrix substrates.
To investigate the mechanism of regulation in p65 activity, we
used protein chip technology to detect changes in signaling
molecules that are associated with the MAPK pathways. We
determined that HBs may phosphorylate AKT and ERK for
activation. However, the pCMV-HBs cells were not protected
from apoptosis and did not exhibit increased migration. We
speculate that HBs activity was inhibited due to JTB. GSK-3 beta
is phosphorylated in vitro at serine 9 by RSK1, resulting in its
inhibition [35]. The activation of RSK1, which is involved in
regulating cell survival and proliferation, lays at the end of the
signaling cascade mediated by the extracellular signal-regulated
kinase (ERK) subfamily of mitogen-activated protein (MAP)
kinases [36]. HBs activated ERK signal pathways. But HBs may
decrease p65 activity following the translocation of JTB into the
cytoplasm. After JTB knockdown, HBs exhibited a stronger
potential to promote tumor progression. We observed that there is
a lower level of GSK-3bphosphorylation and higher level of p65
phosphorylation in HBs+JTBi cells. It has been reported that
GSK-3b can phosphorylate the C-terminal domain (residues354–
551) of p65 in vitro [37]. However, the role of the interaction
between JTB and HBs in GSK-3bphosphorylation is unclear. This
issue will be our research focus in the future. JTB protein and HBs
play different roles in human HCC. HBs may act as an oncogene
that is integrated into the human genome, whereas JTB is
presumably a tumor suppressor gene. Therefore, therapeutic
approaches that are aimed at eliminating HBs and/or reactivating
JTB might be highly useful in the treatment of human liver cancer.
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